Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular and Structural Imaging in Alzheimer's Disease
NCT02740634Recruiting
- Sponsor
- Mayo Clinic
- Start
- May 2016
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of flortaucipir and carbon-11 Pittsburgh compound B in Alzheimer's disease (AD) (2 arms), sponsored by Mayo Clinic. Primary endpoints: Amount of Amyloid protein in the brain at 5 years and Amount of Tau protein in the brain at 5 years. Started May 2016; status: recruiting.
02
Drugs
flortaucipircarbon-11 Pittsburgh compound B
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02740634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02740634.